He has been deeply engaged in veterinary drug research and development for more than 10 years, led the completion of 9 new veterinary drug research and development projects, and obtained 7 national new veterinary drug certificates and 7 national invention patents...... Zheng Chunhong, director of the analysis and research office of Wuhan Huisheng Biotechnology Co., Ltd. (hereinafter referred to as "Huisheng Biotechnology"), is a veritable R&D expert. A few days ago, she was awarded the title of "Airport Skill Master" in the first "Ingenuity Airport Port" skilled talent selection in Dongxihu District.
"Recently, a new veterinary drug has been approved for marketing!" When the reporter saw Zheng Chunhong, who had neat short hair, in the Huisheng Biological Industrial Park located in Xingou Town Street, Dongxihu District, she was overjoyed, and she couldn't see the sleepiness of working overtime for a week in a row.
Immersed in a strong atmosphere of scientific and technological innovation, Zheng Chunhong, who is not confused, is full of energy. The new drug she mentioned is a common anthelmintic drug for dogs and cats - imidacloprid moxictin drops. The drug can effectively cover and eliminate a variety of parasites such as fleas, ticks, nematodes and other parasites in and out of pets.
Brave to bear heavy pressure, always innovative. Over the past 10 years, Zheng Chunhong has grown up with the company.
In 2012, Zheng Chunhong joined Huisheng Biotech after graduating with a master's degree, and was catching up with the company to carry out the quality research and analysis of the national second-class new veterinary drug Mabofloxacin tablets. She quickly integrated into the team and provided strong support for the development of new drugs.
■ Zheng Chunhong instructed team members to carry out experimental research.
Zheng Chunhong made a solid start in the project, and Huisheng Biotech also emerged in the pet drug market with this new drug.
Since then, Zheng Chunhong has been in charge of several projects. Huisheng Bio focuses on R&D and innovation, deeply cultivates the six major sectors of swine, poultry, ruminants, aquatic products, pets and APIs, continuously expands the market with efficient and safe veterinary drug products, and ranks among the leading enterprises in the domestic veterinary drug industry. In 2020, Huisheng Biotech was listed on the Shenzhen Stock Exchange, becoming the first listed company in China with veterinary drug preparations as its main business.
"R&D and innovation must endure loneliness." During the research and development of the national second-class new veterinary drug Tediroxin Injection Project, Zheng Chunhong led the team to "soak" in the laboratory for more than a month, and finally found the best detection method.
Her tenacity inspires every member of the team. "From project approval to approval, the project can be as short as 3 years and as long as 10 years. Sister Hong can calm down and take us to the cold bench of the hot laboratory. Li Zhenxia, who has been in the company for 3 years, commented on Zheng Chunhong.
Sitting on the "cold bench" of the hot laboratory, the R&D team of Huisheng Biotechnology has grown from less than 10 people at the beginning to 100 people today, and has completed the R&D and analysis of more than 20 new veterinary drug projects, filling a number of domestic gaps.
As a leading enterprise in the animal health industry, Huisheng Biotech has always focused on the actual needs of animal health care and accelerated the industrialization process of scientific research achievements.
In recent years, with the society's attention to the safety of animal drugs, traditional Chinese veterinary drugs have gradually attracted attention because of their antibiotic-free and non-drug resistance. Huisheng Biology keenly grasped this trend, established a project in the field of pig medicine, and concentrated on research and development.
■ Zheng Chunhong focuses on experimenting and exploring the truth.
The analysis of traditional Chinese veterinary drugs is different from general chemical drugs, Zheng Chunhong learned from the team of Hubei University of Chinese Medicine, transitioned from traditional chemical drug analysis to traditional Chinese medicine analysis, carried out in-depth integration of production, education and research, thoroughly understood the scientific research achievements of traditional Chinese medicine, and realized the paper "paper into money".
In June 2020, the new drug Poria Polysaccharide Powder was officially launched, successfully breaking the monopoly position of Astragalus Polysaccharide in the market. As one of the important products of Huisheng Company, Poria Cocos Polysaccharide Powder has an annual sales volume of nearly 10 million yuan with its unique curative effect and market demand, showing broad market prospects.
In 2023, Zheng Chunhong led the team to complete the research of the antibacterial drug cefpodoxime tablets, and successfully obtained the national five-category new veterinary drug certificate, realizing the industrial production of the drug. This new drug has a significant effect on canine bacterial skin diseases, and the average annual product sales are expected to reach 10 million yuan, bringing a new treatment option to the pet market.
Tightly organized planning, clear goals, and day-to-day experimentation...... She has participated in 1 sub-project of the major national agricultural science and technology project "Key Technologies for the Creation and Industrialization of Veterinary Biosynthetic Drugs", presided over the formulation and revision of 2 group standards, completed 1 key technology research project of Wuhan Science and Technology, 2 Wuhan Science and Technology Plan projects, applied for 7 national invention patents, and was approved 7 national new veterinary drug certificates and successfully transferred production.
On the eve of "July 1st", Zheng Chunhong was awarded the honorary title of Wuhan Outstanding Communist Party Member.
Produced by Dongxihu District Rong Media Center| Please indicate the source for reprinting
Report support - Dongxihu District Human Resources and Social Security Bureau
Text - Liu Zhicheng
Figure - Xu Yifan
Correspondents - Liu Pengfei Fei Qianru
Poster making - Peng Wei
Editor-in-charge - Wang Gabei
Editor - Dai Donghui